0QF:ETR
Moderna Inc
175,04 €
arrow_upward
+1,97%(+3,38) 1 d.
8. okt., 17:35:47 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: 0QF…
Atvērt
172,72 €
Augsta
178,40 €
Zema
172,32 €
Tirgus kapitalizācija
78,65 mljrd.
Vid. apjoms
29,64 tūkst.
Apjoms
14,40 tūkst.
Augstākā 52 ned.
188,30 €
Zemākā 52 ned.
19,37 €
Darbinieku skaits
5 tūkst.
Atvērt
172,72 €
Augsta
178,40 €
Zema
172,32 €
Tirgus kapitalizācija
78,65 mljrd.
Vid. apjoms
29,64 tūkst.
Apjoms
14,40 tūkst.
Augstākā 52 ned.
188,30 €
Zemākā 52 ned.
19,37 €
Darbinieku skaits
5 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
AD HOC NEWS
·
pirms 1 stundas
Moderna stock gains 0.01 percent after-hours to EUR 174.77 versus the Lang & Schwarz prior close
Yahoo Finance
·
pirms 10 stundām
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
The Motley Fool
·
pirms 19 stundām
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
GuruFocus
·
pirms 1 dienas
Moderna (MRNA) Shares Rise 4.8% Despite Broad Market Weakness on October 7, 2026
Profils
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
Par “Moderna Inc”
ĢenerāldirektorsStéphane Bancel
Darbinieki4,7 tūkst.
Dibināšanas datumssept. 2010
Galvenais birojs-
Sektors-
Tīmekļa vietnemodernatx.com